TX-MOUSER-ELECTRONICS
8.6.2023 19:09:27 CEST | Business Wire | Press release
Mouser Electronics Inc., the industry's leading New Product Introduction (NPI) distributor with the widest selection of semiconductors and electronic components™, launches the next installment of their award-winning Empowering Innovation Together (EIT) series highlighting the Matter protocol. With this installment, Mouser brings together global technology experts from the Connectivity Standards Alliance (CSA) and industry-leading manufacturers to explore all aspects of Matter, from market introduction to design specifications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005018/en/
Matter: One protocol for them all. (Graphic: Business Wire)
With its widespread industry support from leading semiconductor manufacturers, including NXP Semiconductors, Silicon Labs, STMicroelectronics, Schneider Electric, Texas Instruments, Infineon Technologies, Nordic Semiconductor and Microchip Technology Inc., Matter promises to revolutionize smart home technology. In this installment, Mouser provides insights and resources to equip engineers and developers with the knowledge needed to design products that harness the power of this new standard. To review the enlightening new series, visit https://www.mouser.com/empowering-innovation/matter-protocol/.
The Matter series features two new episodes of The Tech Between Us podcast, hosted by Mouser's Director of Technical Content Raymond Yin. In episodes part one and two, Yin is joined by Chris LaPré, Chief Technical Officer at the Connectivity Standards Alliance. The pair cover the market's introduction to Matter and explore the types of smart home devices compatible with the new standard. They also dive into the role the CSA plays with Matter and the future focus areas of interest. A third podcast, In Between the Tech, features an interview with Sujata Neidig, Director of Marketing for Wireless Connectivity at NXP Semiconductors. She'll discuss the types of hardware and software behind the Matter protocol, how it impacts manufacturers when it comes to product design and development, as well as what considerations engineers need to make when designing with Matter.
"Matter provides an exciting and innovative way to connect manufacturers, engineers, and consumers through a unified protocol, " says Raymond Yin, Mouser Electronics' Director of Technical Content and host of The Tech Between Us podcast. "I'm thrilled to see and share how companies and individuals are helping create a world of interconnected devices that bring us together by utilizing the Matter standard."
Through educational interviews, infographics, articles, webinars and blogs, this installment explores topics like how to choose a suitable System-on-Module (SoM) for integration, tips for using Matter in product development, tutorials on developing applications based on Matter and more.
Episode co-sponsors include manufacturers Nordic Semiconductor, Schneider Electric, Texas Instruments, NXP Semiconductors, STMicroelectronics, Silicon Labs, Infineon Technologies and Microchip Technology Inc. Mouser's EIT program continues to deliver a variety of insightful content to complement the conversation on The Tech Between Us podcast.
Following the Matter standard, the EIT series will further explore digital therapeutics, environmental sensors, Wi-Fi 7, and industrial machine vision. It will uncover the technical developments needed to keep pace with the evolving world, as well as highlight various new products in the marketplace. Established in 2015, Mouser's Empowering Innovation Together program is one of the industry's most recognized electronic component programs. To learn more, visit https://www.mouser.com/empowering-innovation/ and follow Mouser on Facebook, LinkedIn, Twitter and YouTube.
For more Mouser news, visit https://www.mouser.com/newsroom/.
About Mouser
Mouser Electronics, a Berkshire Hathaway company, is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 6.8 million products from over 1,200 manufacturer brands. Mouser offers 27 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 650,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/.
Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005018/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom